Member Info for Rob1967

Just imagine if we were on AIM...

barwickman, he openly admitted he sold down from previous highs on a recent podcast and his colleagues had not sold down.
It stinks of trying to get back in, we will never know what would of happened if we'd of had no podcast.

JW's tip on Bids didn't work out...directors selling

Only confirmed that they were in talks...nothing denied though ;-)

10.8p to buy 10.77p sell..tight as...

Looks like a very healthy pullback to me, clear out the traders/non believers and we can all move on.
If The Times figures are accurate then....

No difference whatsoever, we will trade more than that by dinner today.
There’s also a few on here with bigger holdings than that.

Considering we closed 3% too high due to the UT trade, I’d expect us to open around 11.5p.
Not that it really matters, let’s see where we are come xmas and beyond.
Should be a good week though.

More than likely will be as JW and his pals are holders..

https://twitter.com/smallcappick/status/1187592915088035840

Shandy you forget to mention what the Chinese have already paid, we also don't know for sure if they have paid or are in negations for more.
We have also had cash from the eber deal, this is no one trick pony..

Many of of us were lucky to get in at the high 2p's, mainly due to the contributions on here from Aim and Jay, many thanks

Gp, aim and myself have been saying for weeks that something is brewing.
Why have the mm’s been on a buy at any cost for the last two weeks... it’s all adding up now.

#NFX Eastern promise for Nuformix
#Nuformix uses co-crystal technology to re-engineer drugs. Market gossip suggests that Kissei is in talks to license Nuformix’s lead fibrosis treatment alongside its unique oral delivery system
https://twitter.com/smallcappick/status/1187592915088035840

Oz... once confirmed 20p will be a distant memory

Eastern promise for Nuformix?Shares in Nuformix, the Cambridge-based drug company, gave up recent gains yesterday to trade 5 per cent lower and close at 8¼p.
Chatter that Nuformix is close to securing a licensing deal with Kissei Pharmaceutical, one of Japan’s largest drug companies, has sent shares in the minnow higher in recent days.
Nuformix uses co-crystal technology to re-engineer drugs. Market gossip suggests that Kissei is in talks to license Nuformix’s lead fibrosis treatment alongside its unique oral delivery system.
The proprietary delivery mechanism resolves a number of efficacy problems that have plagued Kissei for years, they claim. The partnership could enable Kissei to treat other conditions.
The reports suggest that the deal being discussed involves an upfront milestone payment of £15 million and annual royalty payments worth more than £200 million.
If a deal is struck and structured on those terms, Nuformix would generate revenues well in excess of its current £40 million market value.
Established in 2008, Nuformix set out to identify known drug molecules with the potential to function as innovative therapies for unmet medical needs.

SV, we have a leak in todaysTimes.

I assumed that Rob, was just checking it’s validity.

Any links Rob ?

Barwickman, I did add a smiley at the end...